ArticleJournal of thoracic disease2026
Chemoimmunotherapy improves surgical resection rate and survival versus chemotherapy in potentially resectable non-small cell lung cancer: a real-world propensity score-matched study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoimmunotherapy (nCIT) has become the standard-of-care for resectable non-small cell lung cancer (NSCLC), due to its significant improvements in event-free survival (EFS) and overall survival (OS). However, the feasibility of conversion chemoimmunotherapy (CIT) in potentially resectable NSCLC remains unclear. In this context, this study will provide more reliable real-world data to support the robust efficacy of CIT in patients with potentially resectable NSCLC. Methods: This retrospective analysis enrolled patients with potentially resectable NSCLC who had no active oncogene mutation and underwent conversion therapy at four cancer centers between January 2021 and March 2024. All patients received either chemotherapy (CT) or CIT as conversion regimens. After 1:n propensity score matching (PSM), efficacy and safety were compared between groups using the following endpoints: surgical conversion rate, major pathological response (MPR) rate, pathological complete response (pCR) rate, EFS, and treatment-related adverse events (TRAEs). Results: A total of 334 patients were enrolled, with 252 in the CIT group and 82 in the CT group. After PSM, the final cohort comprised 196 patients in the CIT group and 78 in the CT group. CIT treatment showed significantly higher surgical conversion rate Conclusions: In this retrospective cohort, CIT was associated with higher surgical conversion rates, MPR, pCR, and improved EFS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.